HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Triclosan safety study

This article was originally published in The Rose Sheet

Executive Summary

Will be conducted to support Category I status for the ingredient in the FDA OTC drug monograph for antimicrobial body washes, according to the Triclosan Industry Alliance. The study, a 13-week dermal sub-chronic toxicity study of rats, is expected to begin by year end. Under the protocol, rats will receive 91 daily applications of .3 mg, 1 mg, 3 mg or 5 mg triclosan and be assessed for various endpoints. Members of the alliance include Colgate- Palmolive (Softsoap), Dial (Dial), Procter & Gamble (Safeguard) and Unilever (Lever 2000). The protocol was submitted by Colgate. FDA's NDAC is meeting July 29 to discuss testing requirements for the antimicrobial monograph but is not expected to consider the triclosan protocol...
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS005634

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel